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1Centre for Health Economics & Medicines Evaluation; 2School of Psychology, Bangor University, Bangor, Gwynedd, UKA B S T R A C TObjectives: This review sought to identify the empirical evidence for
the application of models from sociocognitive theory, self-regulation
theory, and social support theory at predicting patient adherence to
medications. Methods: A systematic review of the published literature
(1990–2010) using MEDLINE, EMBASE, Cochrane Library, CINAHL, and
PsychINFO identiﬁed studies examining the application of health psy-
chology theory to adherence to medication in adult patients. Two
independent reviewers extracted data on medication, indication, study
population, adherence measure, theory, model, survey instruments, and
results. Heterogeneity in theoretical model speciﬁcation and empirical
investigation precluded a meta-analysis of data. Results: Of 1756
unique records, 67 articles were included (sociocognitive ¼ 35, self-ee front matter Copyright & 2014, International S
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.1016/j.jval.2014.08.2671
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n Street Building, Bangor University, Bangor, Gwyregulation ¼ 21, social support ¼ 11). Adherence was most commonly
measured by self-report (50 of 67). Synthesis of studies highlighted the
signiﬁcance (Pr 0.05) of self-efﬁcacy (17 of 19), perceived barriers (11 of
17), perceived susceptibility (3 of 6), necessity beliefs (8 of 9), and
medication concerns (7 of 8). Conclusions: The results of this review
provide a foundation for the development of theory-led adherence-
enhancing interventions that could promote sustainable behavior
change in clinical practice.
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Adherence to medications can be deﬁned as the process by which
patients take their medication as prescribed, described by three
quantiﬁable phases: initiation, implementation, and discontinua-
tion [1]. Suboptimal adherence to appropriately prescribed medi-
cines is recognized as one of the major factors contributing to
therapeutic nonresponse [2]. It is highly prevalent across a broad
range of conditions and presents a signiﬁcant challenge to the safe,
effective, and cost-effective use of medicines. It is estimated that
between a third and a half of all medicines prescribed for long-
term conditions are not taken as recommended [2]. Even within
the context of a clinical trial, 50% of the patients discontinue
within the ﬁrst year [3]. In a study of adults diagnosed with
diabetes, hypertension, or dyslipidemia in the United States, the
total direct national cost of nonadherence was estimated to be
$105.8 billion ($453 per adult) [4]. It is argued that improving
adherence to existing medication may generate more health
beneﬁts than any other improvement in medical treatment, yet
research into the causes of suboptimal adherence has been of
variable quality, often contradictory, and generally inconclusive [5].A Cochrane review [6] identiﬁed that simple interventions, such
as written information, improved adherence to short-term medica-
tions but only more complex interventions, such as education with
follow-up, improved adherence to long-term treatments. The review
found that even the most effective interventions did not lead to
large improvements in adherence and health outcome. This is likely
to reﬂect the multiplicity of factors determining adherence and the
lack of attention to existing theories that may explain adherence
behavior. This is also an area of considerable heterogeneity with
respect to patient characteristics, treatments, and illnesses, as well
as adherence measurements and outcome variables.
The biomedical literature is abundant with studies in which
patient and disease characteristics are examined as predictors of
suboptimal adherence. It is argued that such research is based on
a ﬂawed conceptual model, in which variable selection is often
based on availability rather than theoretical foundations [7].
Stavri and Michie [8] recently highlighted the importance of the
application of theory-driven, evidence-based models in the
development of effective interventions. They advocate the devel-
opment of a hierarchical classiﬁcation system of behavior change
techniques, derived from psychological theory, that can be usedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conomics & Medicines Evaluation, Institute of Medical and Social
nedd LL57 1UT, UK.
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evidence-based theories have the potential to be more successful
than interventions based on observed associations with
unknown mechanism for behavior change. This does not, how-
ever, exclude interventions based on other factors, including
actual social context or support, regimen complexity, and cost
of medication, which also have a signiﬁcant impact on adherence
to medication but are beyond the scope of this review.
There are several health psychology theories that have been
used to predict adherence to medications [9]. The most common
applications are of social cognitive theory [10–12], within which
the health belief model [13,14], the theory of reasoned action [15],
and the theory of planned behavior [16] are most prevalent. The
self-regulatory model [17] and the transactional model of stress
and coping [18] have also been used but to a lesser extent.
Variables most often explicitly assessed within these theoretical
models are considered proximal (close) to adherence behavior
[19]; however, it has also been recognized that adherence behav-
ior varies according to more distal variables, such as personality
traits (including, e.g., conscientiousness, extraversion, and neu-
roticism), and more generic beliefs, such as multidimensional
health locus of control [20] and generalized efﬁcacy beliefs [11],
which more likely operate “indirectly” on outcomes. To date,
there has been little consistency in the type of control associated
with adherence to medications [21,22].
Consolidation of existing behavioral models may provide a
theoretical basis for the development and assessment of
adherence-enhancing interventions. Previous reviews of predictors
of a range of health-related behaviors have found that a limited
amount of variance in adult behavior was explained by the health
belief model (10%), the theory of planned behavior (30%), and self-
efﬁcacy (4%–26%) [23–25]. It should be noted, however, that these
reviews relate to pooled estimates of various health-related behav-
iors within which predictors of adherence are likely to vary [26]. As
such, these reviews have more limited generalizability to adher-
ence to medications than those reported in a focused systematic
review. There are clear beneﬁts to theory-led ﬁndings informing the
development of adherence-enhancing interventions, the full poten-
tial of which requires thorough and systematic selection of theory.
This article presents a systematic review of the application of
behavioral models to the study and prediction of adherence to
medications in adult patients. The review adds to the literature by
providing a systematic and critical assessment of 20 years of
empirical evidence on the determinants of adherence to medication
in the context of three theoretical frameworks: the social cognitive
theory, the self-regulation model, and the social support theory.
The review ﬁndings will help to inform conceptual frameworks for
behavior change speciﬁc to adherence, which will further aid the
development and implementation of theory-led adherence-enhanc-
ing interventions that seek to realize the full beneﬁts of medicines.Table 1 – Quality assessment scoring system.
Score Adherence measure
100 Directly observed therapy or electronic compilation of drug do
75 Medication measurement: therapeutic drug monitoring or co
returned tablets
50 Prescription records
25 Self-reported patient questionnaires and diaries
0 Assessment of patients’ clinical responses and/or physiologic
effect
Note. Quality score ¼ (Adherence measure score/2) þ (Study design score
lowest quality.Methods
A systematic review was conducted according to the methods of
the Centre for Reviews and Dissemination [27] and reported
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement [28]. Searches were con-
ducted in MEDLINE via PubMed, EMBASE, the Cochrane Library,
CINAHL, and PsychINFO from January 1990 to March 2010, using a
range of search terms relating to adherence, medicines, theory,
and health psychology, which were then combined using the
Boolean “AND” operator (Appendix 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.08.2671). Additional
studies were also identiﬁed by experts convened at Ascertaining
Barriers to Compliance Project Team internal meetings and by
visually scanning reference lists of eligible studies.
Study Selection
Studies were included if they were published in peer-reviewed
journals, contained empirical data on adherence to prescribed
medicines in adult patients, investigated psychosocial determi-
nants of adherence, and reported speciﬁc reference to an estab-
lished theoretical framework. Studies were excluded if they
concerned vaccines or involved participants who were dependent
on others for the administration of medicine (e.g., children,
inpatients, adults in care homes, or incarcerated). Studies involv-
ing complementary medicines (e.g., herbal remedies and homeo-
pathy) were also excluded on account of these being available
largely without prescription.
Eligibility assessment and data extraction were performed
independently, unblinded, and in duplicate by two reviewers
(E.A.F.H. and M.K./J.P./S.P.). Disagreements in assessment out-
comes were resolved by a third opinion (V.L.M.). Data were
extracted using predeﬁned data ﬁelds on study characteristics,
participant characteristics, adherence measure, application of
health psychology (including theory, model, and instruments
used to measure independent variables), and results of primary
predictive model.
Risk of Bias
A scoring system was introduced to rank studies according to
their quality (Table 1). This weighted three elements of each
study: adherence measure, study design, and sample size. The
method of adherence measure was weighted most because the
extent to which variability may be explained by behavioral
models of adherence depends on the accuracy, precision, and
reliability of the methods used to detect it. Study design was
weighted second, with longitudinal studies considered superior
to cross-sectional analysis given that adherence varies over time.Study design Sample
size
sing histories Randomized controlled trial or
prospective cohort
Z1,000,000
unts of Panel data 10,000–99,999
Retrospective cohort 1,000–9,999
Cross-sectional 100–999
al marker or Case report r99
/3) þ (Sample size score/6). Interpretation: 100 ¼ highest quality, 0 ¼
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 6 3 – 8 7 6 865Sample size was given the least weighting. The resulting overall
quality score captured selection, performance, and detection bias.
Attrition and reporting bias were assessed on an individual basis
by inspecting the results of studies with multiple outcome
measures and incomplete outcome data. All the studies included
in the review were assigned a weighted score.
Evidence Synthesis
The plan for evidence synthesis was speciﬁed a priori and
included an initial descriptive summary of all studies followed
by a meta-analysis of three or more studies that were sufﬁciently
homogeneous (contextually, methodologically, and statistically).
In the event that a meta-analysis was not possible, we planned a
narrative synthesis, using the general framework suggested by the
Centre for Reviews and Dissemination [27]. This involved a
primary synthesis to categorize the studies according to theoret-
ical framework, model, and model components (factors), including
a count of the number of studies that tested the relevant
components and the ratio of how many times it research stat-
istical signiﬁcance (P r 0.05). All results were reviewed, including
those that did not reach statistical signiﬁcance in order to
minimize the risk of selection bias. We then explored the relation-
ships within and between studies by comparison of their applica-
tion and the empirical performance of the postulated theory. This
part of the review was to be restricted to studies of highest quality
to ensure a more robust comparison (quality score Z 50).Results
Study Selection
The search of electronic databases identiﬁed 2309 records; a
further 10 were identiﬁed by experts and bibliographies.2309 records
through database searching
10
identified thr
1756 records 
after duplicates removed
1756 records 
screened by title and abstract
535 full-text articles
assessed for eligibility
67 studies 
included in qualitative synthesis
Fig. 1 – Flow diagramFollowing the removal of duplicates, resulting in 1756 records,
1221 were excluded on the basis of information provided in the
titles and abstracts. Five hundred thirty-ﬁve full-text articles
were assessed for eligibility, and 468 were excluded according
to predeﬁned exclusion criteria (Fig. 1). Sixty-seven studies were
included in the review [29–95] and categorized into three frame-
works: sociocognitive theory (n ¼ 35), self-regulation theory (n ¼
21), and social support theory (n ¼ 11).
Study Characteristics
The characteristics of individual studies are summarized in
Table 2.
Study design and participants
Studies were mainly cross-sectional (n ¼ 49). Most of the studies
reported participants on long-term treatment for chronic diseases
with a mean age range of 34.1 to 80.5 years. The most common
therapeutic indications were human immunodeﬁciency virus (HIV)
(n ¼ 22), hypertension (n ¼ 8), and mental health disorders (n ¼ 6).
Adherence measure
Self-report was the most common method of adherence meas-
urement (n ¼ 50) (Table 3) usually by questionnaire (n ¼ 24) such
as the Medication Adherence Rating Scale [59] (n ¼ 5) and the
Morisky questionnaire [96] (n ¼ 5). Half of the longitudinal studies
used electronic compilations (9 of 18); within these studies, there
was heterogeneity in the follow-up period and the threshold used
to classify patients as being adherent (which ranged from 450%
to Z95% doses registered as being taken).
Theoretical models
Studies most commonly used the health belief model (n ¼ 20),
self-regulation theory (n ¼ 16), social support theory (n ¼ 5), records
ough other sources
1221 records excluded:
Publication type: 209
Wrong topic: 640
Non-empirical: 365
Language: 7
468 records excluded:
Wrong topic: 5
Non-empirical: 207
No health psychology variables: 145
No predictive model: 12
Post-hoc application of theory: 71
Study sample: 28
9 studies assessed for quantitative 
synthesis
of study selection.
Table 2 – Selected characteristics of studies presented in order of study design followed by bias assessment score (longitudinal to cross-sectional,
least to most prone to bias).
First author
N (model n)
Therapeutic
indication/
medication
Age, mean
 SD (y),
% of males
Adherence measure
(time)*
Theory: Model
Instrument(s)†
Key ﬁndings‡ Quality
score§
Longitudinal studies
Gonzalez [29]
N ¼ 325
(325)
HIV Antiretroviral 41  8.5, 60 E: MEMS (490%, 15 mo) SRT: SRM Structural equation model: Education|| Pill burden||
Symptoms|| Necessity (speciﬁc)|| Concerns (speciﬁc)||
Distrust (general)||. Mediators: Distrust by concerns||
Beneﬁts by concerns|| Beneﬁts by necessity||
87
S: ACTG BMQ customized
Weaver [30]
N ¼ 322
(322)
HIV Antiretroviral 41  8.5, 58 E: MEMS (490%, 15 mo) SS: TMSC COPE,
SPS, ISEL
Structural equation model: Age|| Education, Income,
Employment, Time since diagnosis|| Regimen burden,
Avoidant coping||. Mediators: Negative mood avoidant
coping¶ SS by avoidant coping||
87
S: ACTG
Halkitis [31]
N ¼ 300
(300)
HIV Antiretroviral 42  7.7, 100 E: MEMS (2 wk) SS: Coping/SE Structural equation model: Drug use|| Socioeconomic status||.
Mediators: Psychological state by drug use||
87
S: Interview Customized
Lynam [32]
N ¼ 189
(189)
HIV Antiretroviral 73# E: MEMS (1 wk) SRT: SDT TSRQ,
MHLC, SE-
customized
Structural equation model: MHLC Internal, MHLC Chance,
MHLC External¶ MHLC Powerful others, SE¶. Mediators:
Autonomous regulation by SE¶
87
Barclay [33]
N ¼ 185 (140)
HIV Antiretroviral 44  7.3, 78 E: MEMS (Z95%, 1 mo) SCT: HBM ext.
AADQ, MHLC,
SE-customized
Young (n ¼ 140, age 41  5.0 y) Drug abuse/dependence,
Financial resource, Apathy/Indifference, MHLC Internal,
MHLC Chance, SE|| Perceived utility¶ Intention, Subjective
norms, Support/Barriers
87
Old (n ¼ 45, age 56  4.8 y) Income, Sexual orientation, Global
cognitive function|| MHLC Internal, Subjective norms
Stilley [34]
N ¼ 158
(158)
Cholesterol Lovastatin 46  8.7, 54 E: MEMS (Z80%, 12 wk) Distal: 5-FM NEO
PI-R
Depression|| Anxiety|| Conscientiousness¶ IQ¶ Mental
ﬂexibility/Perceptual organization
87
Schmitz [35]
N ¼ 97 (97)
Smoking Bupropion SR 49  9.9, 0 E: MEMS (450%, 7 wk) SCT: HBM HABQ Symptoms, Adherence feedback¶ Perceived barriers 83
Apter [36]
N ¼ 88 (85)
Asthma Inhaled
corticosteroids
47  15, 28 E: MDILog (42 d) SCT: HBM/TRA
Customized
Race/Ethnicity|| Symptoms, Treatment knowledge, Inhaled
adherence scale, Attitude¶
83
Cohen [37]
N ¼ 65 (57)
Depression
Antidepressant
41  11.4, 42 E: MEMS (14 wk) Distal: 5-FM NEO
PI-R
NEO PI-R Activity¶ NEO PI-R Feeling, NEO PI-R Modesty¶ 83
Brus [38]
N ¼ 65 (55)
Rheumatoid arthritis
Sulphasalazine
59  #, 20 M: Pill count (Z80%, 3 mo) SCT: SLT
Customized
Age, Sex, Education, Health status, Symptoms, Disease
severity, Patient education, SE¶ Barriers, Outcome
expectation, Perceived social attitude, Perceived SS
71
Abraham [39]
N ¼ 176
(167)
Malaria Meﬂoquine
Chloroquine þ
Proguanil
41#, 34# S: Interview or
questionnaire (at 6–7
wk)
SCT: HBM/TPB
Customized
Meﬂoquine (n ¼ 106) Adherence in malarious region,
Perceived severity, Perceived susceptibility, Perceived
adverse effects|| Perceived behavioral control (PBC),
Intention¶ Attitude, Injunctive norm
50
Chloroquine þ Proguanil (n ¼ 61) Adherence in malarious
region¶ Perceived severity, Perceived susceptibility,
Perceived adverse effects, PBC, Intention, Attitude,
Injunctive norm
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Simoni [40]
N ¼ 136
(136)
HIV Antiretroviral 43  8.9, 55 S: ACTG (at 3 mo) SS: SSI, SBI Structural equation model: SE||. Mediators: Negative affect by
SE¶ Spirituality by SE¶
50
Williams [41]
N ¼ 186
(126)
Outpatients# (Z 1 mo) 56  #, 25 S: Pill count (at 14 d) SRT: SDT MHLC,
TSRQ, HCCQ
Structural equation model: Autonomous motivation||.
Mediators: Autonomy support by autonomous motivation||
50
Lim [42] N ¼
136 (126)
Geriatric
polypharmacy
81  8.1/80
 7.7, 35
S: Interview (0 and 2 mo) SCT: HBM
Customized
Pharmacist intervention, Hospitalization in last 6 mo, ADL,
Responsibility for medicines taking, Number of medication
remembering methods, Barriers, Beneﬁts, Severity||
50
Farquharson
[43] N ¼
130 (94)
Malaria Prophylaxis 37  13.1, 57 S: Interview (at 4.5
wk [4–7])
SCT: HBM/TPB
Customized
Full vs. Poor (n ¼ 80) Beneﬁts, Intentions, Length of stay,
Information/questions, Adherence barriers discussion.
MLR: Full vs. Partial (n ¼ 94) Beneﬁts¶ Intentions, Length of
stay¶ Information/questions|| Adherence barriers
discussion. Partial vs. Poor (n ¼ 40) Beneﬁts, Intentions,
Length of stay¶ Information/questions¶ Adherence barriers
discussion
50
Fraser [44]
N ¼ 108
(104)
Multiple sclerosis
Glatiramer acetate
43  8.8/45
 9.5, 11
S: Interview or e-mail
(discontinued/
continued at 6 mo)
SCT: Control
Beliefs MSSE,
SES
Individual hypotheses: SE total¶ SE control¶ SE function¶
Hope, Mobility¶ Spasticity¶ Fatigue-baseline||
50
Turner [45]
N ¼ 89 (85)
Multiple sclerosis DMT 51  9.3, 80 S: Interview (per month
for 6 mo)
SCT: HBM ADQ,
BACS
2 mo (n ¼ 67) Age, Sex, Race, Years with MS, DMT type, Time
on DMT, Cognitive status, Barriers, Beneﬁts|| Severity,
Susceptibility
46
4 mo (n ¼ 80) Age,|| Sex, Race, Years with MS,|| DMT type, Time
on DMT, Cognitive status, Barriers, Beneﬁts|| Severity,||
Susceptibility
6 mo (n ¼ 85) Age, Sex, Race, Years with MS, DMT type, Time
on DMT, Cognitive status, Barriers, Beneﬁts|| Severity,
Susceptibility
Rudman [46]
N ¼ 201
(190)
Renal
Immunosuppressant
39  #, 56 C: Laboratory report calls
(over 12 mo)
SCT: PMT
Customized
Structural equation model: Age at transplant|| Adverse effects
complaints¶ MHLC External, SE¶ Threat appraisal||
Protection motivation, Response costs, Response efﬁcacy
21
Cross-sectional studies
Johnson [47]
N ¼ 244
(244)
HIV Antiretroviral 56  4.8, 71 S: ACTG SS: TMSC ext.
PSR, WOC, CWI
Structural equation model: Time since diagnosis¶ Negative
affect¶ Maladaptive coping¶ Perceived SS¶
29
George [48]
N ¼ 819
(350)
Heart failure Medication 62  12.6, 72 P: Reﬁll data (Z90%,
14 mo)
SCT: HBM ext.
BMQ, MHLC
and customized
Born in North America, Smoker|| Use of medications BD or
less¶ Morisky score 4 0, Use of antidepressants, Use of
adherence aids, Self-reported adherence (%), Have you
changed daily routine to accommodate your medication
schedule¶ Perceived beneﬁts
37
Chisholm
[49] N ¼
158 (158)
Renal
Immunosuppressant
51  12.4, 60 P: Reﬁll data (Z80%, 3 mo) SCT: TPB
Customized
Structural equation model: Past behavior¶ Intention||
Subjective norms, PBC, Attitude. Mediators: Attitudes by
intentions, PBC by intentions
37
Orensky [50]
N ¼ 125
(75)
Anticoagulation
Warfarin
60  #, 49 P: Reﬁll data (Z80%, 6 mo) SCT: HBM
Customized
Structural equation model: 1) Prescription reﬁll ¼ Divorced/
never married¶ Perceived barriers¶. 2) Self-report ¼ Living in
a shelter|| Living with a friend or relative|| Perceived barriers¶
37
S: Questionnaire
Johnson [51]
N ¼ 2765
(2478)
HIV Antiretroviral 41/42, 69 S: Computerized
interview (Z90%, 3 d)
SRT: SAT SPS and
customized
Race/Ethnicity¶ Current crack cocaine use|| Injection use¶
Homeless/shelter|| In primary relationship¶ Doses/day¶ SE¶
Symptom bother¶ Treatment beliefs|| Coping SE¶ Necessity
beliefs¶ SE-beliefs¶
29
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Table 2 – continued
First author
N (model n)
Therapeutic
indication/
medication
Age, mean
 SD (y),
% of males
Adherence measure
(time)*
Theory: Model
Instrument(s)†
Key ﬁndings‡ Quality
score§
Horne [52]
N ¼ (1871)
IBD Maintenance
therapies
50  16.0, 37 S: MARS 4 items SRT: SRM BMQ,
IPQ-R chronicity
only
Age¶ Sex, Outpatient visits¶ GP visits, Inpatient visits, Time
since diagnosis¶ Diagnosis, Attitudinal groups compared
with accepting: Ambivalent¶ Indifferent¶ Sceptical¶
29
Greenstein
[53] N ¼
1402 (1223)
Renal
Immunosuppressant
47  12.5, 49 S: Questionnaire (previous
4 wk)
SRT: SRM
Customized
Age¶ White collar¶ Time since transplant|| Need drugs even if
my kidney is functioning well|| Drugs should never be
delayed¶ Immunosuppressants stay active in my system
for Z24 h||
29
Byrne [54]
N ¼ 1611
(933)
Coronary heart disease
Preventative
66  9.1, 65 S: MARS 5 items SRT: SRM BMQ,
IPQ-R
Age|| Sex, General Medical Services eligible¶ GP consultations,
Time since diagnosis, Previous MI, Cause-stress, Cause-
heredity, Cause-own behavior, Identity, Timeline-chronic¶
Consequences, Personal control, Treatment control,
Coherence, Timeline-cyclical, Emotional representations,
Necessity (speciﬁc)¶ Concerns (speciﬁc)¶ Harm (general)¶
Overuse (general)¶
25
De Smet [55]
N ¼ 1270
(573)
Asthma Inhaled
corticosteroids
41  2.4, 29 S: Questionnaire SCT: HBM ext.
Customized
SF-36 MCS, Years since diagnosis, Perceived barriers¶
Perceived beneﬁts¶ Perceived severity¶ Enabling
25
Johnson [56]
N ¼ 545
(545)
HIV Antiretroviral 43  7.8, 81 S: ACTG (Z90%, 3 d) SS: SP-S SPS,
SPSI-R
Structural equation model: Age, Sex, Ethnicity, Alcohol, drug
use, Psychological health†. Mediators: Constructive SP-S by
Psychological Health¶ Dysfunctional SP-S by Psychological
Health¶
25
Ross [57] N ¼
514
Hypertension
Antihypertensive
60  12.2, 52 S: Morisky 4 items SRT: BMQ, IPQ-R Age¶ Emotion¶ Personal control|| Necessity (speciﬁc)¶ 25
Chao [58] N ¼
1700 (445)
Diabetes (type 2) Oral
hypoglycemic
56  11.4, 50 S: Morisky/Horne 4 item SCT: HBM ext.
Customized
Structural equation model: Depression, SE¶ Perceived
barriers¶ Perceived beneﬁts, Perceived severity, Perceived
susceptibility, Perceived adverse effect barriers¶
25
Horne [59]
N ¼ 324
Chronic multiple # S: Questionnaire SRT: BMQ Age¶ Illness group: cardiac¶ Illness group: asthma¶ Necessity-
concerns (differential)¶
25
Youssef [60]
N ¼ 316
Hypertension
Antihypertensive
59  9.2, 60 S: Questionnaire (Z90%, 1
mo)
SCT: HBM
Customized
Controlled blood pressure¶ Restriction of dietary salt and fat¶
Perceived beneﬁts¶ Perceived susceptibility¶ Drug adverse
effects||
25
Chen [61]
N ¼ 277
Hypertension
Antihypertensive
66  12.3, 60 S: Medication Adherence
Inventory þ customized
SRT: SRM IPQ-R Age, Live alone|| History hyperlipidemia||/hypertension, SBP,
Drug number, Identity, Symptoms after-yes, Symptoms
after-uncertain, Timeline, -cyclical, Consequence, Personal
control, Treatment control|| Coherence, Emotional,
Balanced, Psychological¶ Cultural, Risk||
25
Gatti [62] N ¼
301 (275)
Pharmacy patients Not
reported
54  12.5, 27 S: Morisky 8 items SRT: SRM BMQ,
SEAMS
Ageo65 y¶ Literacy level of less than high school, Self-report
of hyperlipidemia|| Low SE¶ BMQ (score Z47)¶
25
Phatak [63]
N ¼ 250
Chronic multiple #, 38 S: Morisky 9 items SRT: SRM BMQ Age¶ Conditions, Medications(n)|| Necessity (speciﬁc)||
Concerns (speciﬁc)¶ Harm (general), Overuse
(general)
25
Brown [64]
N ¼ 300
(241)
Hypertension
Antihypertensive
62  #, 31 S: Interview (last 30 d) SCT: HBM
Customized
Age|| Sex, Education, Poverty status, Perceived barriers-
forgetting¶ Perceived barriers-reﬁll, Perceived beneﬁts,
Perceived adverse effect barriers¶
25
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Clatworthy
[65] N ¼
259 (223)
BPD Antimanic 48  11.2, 36 S: MARS 5 items SRT: SRM BMQ Age, Sex, Age of diagnosis, Medications (n), Depression,
Symptoms, Necessity (speciﬁc)¶ Concerns (speciﬁc)¶
25
Roh [66] N ¼
219 (219)
Hypertension
Antihypertensive
65  8.5, 61 S: Hill-Bone Compliance
to High Blood Pressure
Therapy Scale
SRT: SAT GSES,
PRA, KHS,
MOS-SSS
Structural equation model: Knowledge, SE||. Mediators:
Depression by SE|| SS by relationship and SE||
25
Cha [67] N ¼
215
HIV Antiretroviral 41  7.6, 67 S: Morisky SS: ISEL Structural equation model: SE¶. Mediators: Depression by SE¶
Perceived SS by self-efﬁcacy beliefs¶
25
Sud [68] N ¼
238 (208)
Acute coronary
syndromes
65  13.0, 61 S: Medication Adherence
Scale
SRT: SRM BMQ Age, Sex, Race, Education, Number of other people, Heart-
related health status¶ Comorbidities, Necessity (speciﬁc)¶
Concerns (speciﬁc), Harm (general), Overuse (general)
25
Nageotte [69]
N ¼ 260
(202)
Chronic mental health
Neuroleptic
35  8.8, 68 S: Interview SCT: HBM
Customized
Sex, Race, Marital status, Urban/rural residence, Perceived
barriers¶ Perceived beneﬁts, Perceived threat|| Perceived
adverse effect barriers
25
Kennedy [70]
N ¼ 205
(201)
HIV Antiretroviral 40  #, 85 S: Interview SRT: SDT HCCQ,
TSRQ, þ SE
Structural equation model: Psychological distress¶ Perceived
competence¶
25
P: Reﬁll data for
veriﬁcation n ¼ 40
Autonomous motivation mediated by perceived
competence¶ Autonomous support mediated by
psychological distress¶
Ponieman
[71] N ¼
259 (201)
AsthmaInhaled
corticosteroids
48  13, 18 S: MARS 10 items SRT: SRM BMQ SE¶ Necessity (speciﬁc)¶ Concerns (speciﬁc)¶ Regimen hard to
follow||
25
Amico [72]
N ¼ 200
(200)
HIV Antiretroviral 39  8.9, 65 S: ACTG-reversed SCT: IMB IMB
questionnaire
Structural equation model: Adherence Behavioral Skills||.
Mediators: Adherence information by adherence
behavioral skills|| Adherence motivation by adherence
behavioral skills||
25
Richardson
[73] N ¼
201 (197)
Hypertension
Antihypertensive
54  13.1, 22 S: Interview C: Blood
pressure
SCT: HBM
Customized
Age|| Duration of treatment|| Salt restriction, Low net barriers,
Medium net barriers|| Perceived barriers||
25
Pomeroy [74]
N ¼ 225
(184)
HIV Antiretroviral 43  7.3, 78 S: Medication Adherence
Scale
SCT: IMB ext.
SSRS þ
customized
Children in household, Medical care within 1 y of diagnosis,
Receiving mental health services|| Intention¶ Information¶
Motivation-vulnerability|| Motivation-provider, Perceived
SS
25
Cox [75] N ¼
179
HIV Antiretroviral 37  7.7, 91 S: Patient rated and
clinician rated
SS: Customized Discriminant function analysis: Employment|| Symptoms||
Emotional support (actual)||
25
Brewer [76]
N ¼ 169
High cholesterol
Cholesterol-lowering
67  10, 61 S: Questionnaire SRT: SRM
Customized
Age, Sex, Ethnicity, Education, Smoker, CHD, Hypertension,
Diabetes, Medication adverse effects¶ Number of
medications, Consequences|| Timeline,
Cause, Cure, Symptoms
25
C: Blood cholesterol
Valeberg [77]
N ¼ 164
(140)
Cancer Analgesic 58  11.4, 21 S: Questionnaires SCT: HBM ext.
Customized
Sex, Average pain score, Opioid or other pain medication¶
Pain relief¶ SE¶
25
Kopelowicz
[78] N ¼
155
Schizophrenia
Antipsychotic
34  10.8, 63 S: Treatment Compliance
Interview
SCT: TPB TPB
Inventory
PBC¶ Attitude, Subjective norms¶ 25
Mann [79]
N ¼ 151
(150)
Type 2 diabetes PO
Hypoglycemic
57  11, 55 S: Morisky 4 items SRT: SRM IPQ,
BMQ
þCustomized SE
SE|| Necessity (speciﬁc), Concerns (speciﬁc)|| Disease beliefs||
Regimen hard to follow||
25
continued on next page
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Table 2 – continued
First author
N (model n)
Therapeutic
indication/
medication
Age, mean
 SD (y),
% of males
Adherence measure
(time)*
Theory: Model
Instrument(s)†
Key ﬁndings‡ Quality
score§
Ferguson [80]
N ¼ 149
(149)
HIV Antiretroviral 39  8.6, 87 S: PMAQ [part 1] SCT: HBM
barriers only
PMAQ [part 2]
KAMED Qualities of Medicine Schedule and Memory score||
SS, Qualities of medicine|| Schedule|| Memory||
25
Sajatovic [81]
N ¼ 140
(140)
BPD Antimanic #, 50 S: Tablets Routine
Questionnaire
SCT: Attitudes/
control AMSQ,
ITAQ, MHLC
Age, Sex, Ethnicity, Education, Drug addiction¶ Illness
duration, Psychiatric rating scale, Depression, Clinical
Global Impression|| ISEL, MHLC Internal, MHLC Chance,
MHLC Powerful others|| AMSQ¶ ITAQ¶ Rating of Medication
Inﬂuences (ROMI)¶
25
Bane [82]
N ¼ 139
Hypertension
Antihypertensive
52  12.1, 51 S: Questionnaire SCT: SE/TPB
Customized
Perceived behavioral control¶ Intention, Attitude¶ Subjective
norms.
25
Note. Statistically signiﬁcant difference in SE scores between
adherent and nonadherent groups but this was not entered
into the TPB regression.
Atkinson [83]
N ¼ 137
(130)
HIV Antiretroviral 40  6.8, 74 S: ECAB SS: TMSC ECAB Structural equation model: SE|| Optimism|| Social isolation.
Mediators: Stress by optimism|| Psychological distress by
patient-doctor relationship and optimism|| SS by SE||
25
Holstad [84]
N ¼ 120
(115)
HIV Antiretroviral 37  8.5, 60 S: Antiretroviral General
Adherence Scale
SCT: HBM/TRA
AADQ adapted
Sex, Alcohol, Years HIV¶ Existential well-being, Perceived
severity, Support/Barriers¶
25
Schmid-
Mohler [85]
N ¼ 114
(110)
Renal
Immunosuppressant
54  11.9, 65 S: BAASIS SCT: IMBP
Customized
Barrier-feeling overwhelmed, Barrier-practical difﬁculties
during intake, Barrier-no medication aids, Barrier-
forgetfulness/interruption of daily routine|| Intention
25
C: Nurse/Doctor reports
Hekler [86]
N ¼ 139
(102)
Hypertension
Antihypertensive
62  10.2, 34 S: Interview SRT: SRM
Customized
Age|| Sex, BMI, Education, Marital status, Time since
diagnosis, Consequences, Timeline, Identity, Timeline-
cyclical, Control/cure beliefs, Disease cause/control
25
Horne [87]
N ¼ 119
(100)
Asthma Inhaled
corticosteroids
49  18.8, 39 S: MARS 9 items SRT: SRM IPQ,
BMQ
Age, Sex, Education, Number of family doctor visits, Number
of asthma-related hospital admissions|| Duration of
asthma, Consequences¶ Timeline, Identity, Cure, Necessity
(speciﬁc)¶ Concerns (speciﬁc)¶
25
Starace [88]
N ¼ 100
(100)
HIV Antiretroviral 39  7.3, 69 S: ACTG SCT: IMB IMB
questionnaire
Structural equation model: Adherence Behavioral Skills||.
Mediators: Adherence information by adherence
behavioral skills|| Adherence motivation by adherence
behavioral skills||
25
van
Servellen
[89] N ¼ 85
(77)
HIV Antiretroviral 40  8.9, 90 S: ACTG SS: MOS-SSS þ
customized
Months of antiretroviral treatment, Treatment
knowledge, Depression, SE, Emotional support (actual)||
Patient-provider relationship¶
21
Frain [90]
N ¼ 76 (76)
HIV Antiretroviral 30–39, 81 S: Questionnaire SS: FRT FIRM CD4 count, Health worries, Financial worries, Disclosure
worries, Life satisfaction|| Provider trust¶ Overall
functioning, Medication concerns (QOL item), Sexual
functioning, Global distress, HIV mastery¶ Optimism||
Uncertainty, Family resiliency
21
continued on next page
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Muma [91]
N ¼ 66 (52)
HIV Antiretroviral #, 83 S: Questionnaire SCT: HBM
Customized
Ethnicity¶ Perceived barriers-problems taking and scepticism
about medication||
21
C: Erythrocytes
Simoni [92]
N ¼ 50 (50)
HIV Antiretroviral 41  8.0, 38 S: ACTG SS: SSI þ
customized
Depression¶ Anxiety|| SE, SS (actual), Perceived SS, Treatment
knowledge
21
Fraser [93]
N ¼ 594
(199)
Multiple sclerosis
Glatiramer acetate
46  #, 24 C: Record review
(continued/
discontinued at 1 y)
SCT: Control
Beliefs MSSE,
SES
Individual hypotheses: SE control|| SE function¶ Hope, Self-
esteem, Perceived support from spouse|| Perceived support
from physician||
8
Christensen
[94]
N ¼ 112
(72)
Renal Not reported 46  #, 54 C: Serum K levels/Serum P
levels
Distal: 5-FM NEO
Five-factor
Inventory
Age|| Conscientiousness|| 8
Budd [95]
N ¼ 40 (40)
Schizophrenia
Neuroleptic
49  #, 75 C: Accepted medication
(433%, 12 mo)
SCT: HBM
Customized
Discriminant function analysis: Beneﬁts, Severity, Perceived
susceptibility¶
8
Note. ADL, activities of daily living; BD, twice daily; CHD, coronary heart disease; ext., extended; GP, general practitioner; MI, myocardial infarction; PO, oral administration; QOL, quality of life;
SBP, systolic blood pressure. Diseases: BPD, borderline personality disorder; DMT, disease-modifying therapy; HIV, human immunodeﬁciency virus; IBD, inﬂammatory bowel disease. Adherence
measures: ACTG, Adherence to Combination Therapy Guide; BAASIS, Basel Assessment of Adherence to Immunosuppressive medications Scale; ECAB, Elicitation of Compliance and Adherence
Behaviours Questionnaire; MARS, Medication Adherence Rating Scale; MEMS, Medication Event Monitoring System; PMAQ, Patient Medication Adherence Questionnaire. Theory/models: 5-FM,
ﬁve-factor model; FRT, family resiliency theory; HBM, health belief model; IMB, information motivation and behavioral skills; IMBP, integrated model of behavioral prediction; PMT, protection
motivation theory; SAT, social action theory; SCT, sociocognitive theory; SDT, self-determination theory; SE, self-efﬁcacy; SLT, social learning theory; SP-S, social problem-solving; SRM, self-
regulation model; SRT, self-regulation theory; SS, social support; TMSC, transactional model of stress and coping; TPB, theory of planned behavior; TRA, theory of reasoned action. Instruments:
AADQ, Antiretroviral Adherence Determination; ADQ, Adherence Determinants Questionnaire; AMSQ, Attitudes towards Mood Stabilisers Questionnaire; BACS, Barriers to Care Scale
Questionnaire; BMQ, Beliefs about Medicines Questionnaire; COPE, COPE Inventory; CWI, Coping with Illness Scale; FIRM, Family Inventory of Resources for Management; GSES, General Self-
efﬁcacy Scale; HABQ, Health Awareness and Beliefs Questionnaire; HCCQ, Health Care Climate Questionnaire; IPQ(-R), Illness Perceptions Questionnaire (Revised); ISEL, Interpersonal Support
Evaluation List; ITAQ, Insight and Treatment Attitudes Questionnaire; KHS, Knowledge of Hypertension Scale; MHLC, Multidimensional Health Locus of Control; MOS-SSS, Medical Outcomes
Study Social Support Survey; MSSE, MS Self-efﬁcacy Scale; NEO PI-R, NEO Personality Inventory; PMAQ, Patient Medication Adherence Questionnaire; PRA, Patient Reactions Assessment; PSR,
Provision of Social Relations Scale; SBI, System of Belief Inventory; SCI, Self as Carer Inventory; SEAMS, Self-efﬁcacy for Appropriate Medication Use Scale; SES, Rosenberg Self-Esteem Scale; SF-
36 MCS, short-form 36 health survey mental component summary; SPS, Social Provisions Scale; SPSI-R, Social Problem Solving Inventory-Revised; SSI, UCLA Social Support Inventory; SSRS,
Social Support and Reciprocity Scale; TSRQ, Treatment Self-regulation Questionnaire; WOC, Ways of Coping Questionnaire.
* Adherence measures categorized as follows: C, clinical indicator/proxy; E, electronic device; M, mediation measurement; P, prescription records; S, self-report.
† Primary model and instrument(s) used to test primary model.
‡ Regression model unless otherwise stated.
§ Quality score interpretation: 100 ¼ highest quality, 0 ¼ lowest quality.
|| P r 0.05.
¶ P r 0.01.
# Data not available in speciﬁed format.
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Table 3 – Studies categorized by theoretical framework, adherence measurement, and quality.
Adherence measure Sociocognitive theory Self-regulation theory Social support theory
n
Quality score median
(range)
n
Quality score median
(range)
n
Quality score median
(range)
Electronic compilation 5 83 (83–87) 2 87 (87) 2 87 (87)
Medication
measurement
1 71 (71)
Prescription record 3 37 (33–37)
Self-report 22 25 (21–50) 19 25 (25–50) 9 25 (21–50)
Clinical indicator 4 8 (8–21)
Note. Quality score interpretation: 100 ¼ highest quality, 0 ¼ lowest quality.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 6 3 – 8 7 6872theory of planned behavior (n ¼ 3), self-determination theory (n ¼
3), and the transactional model of stress and coping (n ¼ 3). Five
studies tested more than one model within the same theoretical
framework (sociocognitive), though there were no studies that
compared models across frameworks.
All studies included more distal background factors alongside
the independent variables speciﬁed within the theoretical model.
Studies most commonly found associations (P r 0.05) between
adherence and age (13 of 22) and time since diagnosis (5 of 12).
Quality assessment
Across the whole sample, the mean quality assessment score
was 36 (median 25; range 8–87) (Table 2). Use of unweighted
scoring as opposed to weighted scoring had no discernible effect
on the order of studies when ranked by score. Several studies
used ﬁnancial incentives for participation, which may have
introduced response bias [36,41,47,55,72,76,83]. Most of the stud-
ies reported both signiﬁcant and nonsigniﬁcant predictors.
Synthesis of Results
Quantitative synthesis
There was considerable heterogeneity in terms of populations,
theoretical and conceptual deﬁnition, adherence deﬁnition,
adherence measurement, application of relevant theory in terms
of independent variable selection, independent variable meas-
urement (including use of validated instruments), study duration,
and presentation of outcomes (Table 2). Nine studies were
identiﬁed as using the same combination of adherence measure
and health psychology measure as at least two other studies, and
potentially amenable to meta-analysis [52,54,57,62,63,65,71,
79,87]. On closer inspection, however, there were differences in
the population they were applied to, the use of adherence and
health psychology measures, and the data reported. The case for
meta-analyses was consequently dismissed. Combining the
explanatory power of models used to predict adherence to
heterogeneous medications by heterogeneous populations could
compromise the systematic and rigorous representation of
empirical evidence that is more accurately reported in our
narrative synthesis [27,97].
Narrative synthesis
Table 4 summarizes predictors of medication adherence identi-
ﬁed by model and factor, within their associated theoretical
framework. It was not possible to compare the effect size because
of heterogeneity in the measurement of both dependent and
independent variables. Ratios of how many times factors reached
statistical signiﬁcance therefore provide a basis for a narrative
summary of the direction of the empirical evidence for each
factor, cross-referenced by study.Self-efﬁcacy was identiﬁed as the most prominent and sig-
niﬁcant determinant of adherence within sociocognitive theory (7
of 7), self-regulation theory (6 of 6), and social support theory (4 of
6). Signiﬁcant associations with adherence were also frequently
reported between components of the health belief model (per-
ceived barriers ¼ 11 of 17; perceived susceptibility ¼ 3 of 6;
perceived adverse effects ¼ 4 of 5; perceived beneﬁts ¼ 5 of 11),
the self-regulation model (beliefs about medicine necessity ¼ 8 of
9; concerns about medicines ¼ 7 of 8), and the theory of planned
behavior (perceived behavioral control ¼ 2 of 4). Although widely
entered, illness representations were rarely found to be associ-
ated with adherence. It should be noted, however, that two
studies assessing illness representations were omitted from
Table 4 because of inconsistency in their use of illness represen-
tation measures [79] and ambiguous use of customized items [53].
Direct comparison of models within the social-support frame-
work was not possible because of the common use of structured
equation models displaying unique mediated relationships.
Comparative Performance of Models (in Studies with Quality
Assessment Score Z50)
Further assessment of studies of the highest quality maintained
the ﬁnding that self-efﬁcacy was a consistent predictor of
adherence. Applications of sociocognitive theory showed limited
utility of the health belief model because most of the items failed
to reach statistical signiﬁcance and when they did, they
explained a limited proportion of the variance in adherence.
The prediction of adherence increased, however, when used in
conjunction with the theory of planned behavior and
self-efﬁcacy. Barclay et al. [33] found that perceived utility and
self-efﬁcacy were highly signiﬁcant predictors of adherence to
antiretroviral therapy for younger participants and correctly
classiﬁed 73% of the cases. In comparable populations of people
prescribed malaria prophylaxis, Abraham et al. [39] found that
the theory of planned behavior components explained approx-
imately 40% to 50% of the variance in adherence to two different
medications and Farquharson et al. [43] found that perceived
beneﬁts of medication (a single factor of the health belief model),
length of stay, and health professional discussion about adher-
ence and travelers’ questions independently predicted adherence
among 73% of their population. Brus et al. [38] identiﬁed self-
efﬁcacy as the only factor determining adherence (P r 0.01).
Fraser et al. [44] also found that self-efﬁcacy correctly classiﬁed
98.8% of the cases at 6-month follow-up.
Applications of self-regulation theory highlighted compo-
nents of the self-regulation model and autonomous regulation
as being signiﬁcant predictors of adherence to medications.
Symptoms, medication concerns, medication necessity, and dis-
trust were found to predict up to 24% of the variance in
adherence to antiretroviral therapy [29]. There was no evidence
Table 4 – Summary of psychological predictors of medication adherence identiﬁed in the review, presented by
theory, model, and factor.
Independent variable Measured n/N* Reference no. signiﬁcant/nonsigniﬁcant
Proximal: General control beliefs
Self-efﬁcacy (total) 17/19
With sociocognitive theory 7/7 33, 38, 44, 46, 58, 77
With self-regulation theory 6/6 32, 51, 62, 66, 71, 79, 93
With social support theory 4/6 40, 67, 83, 90/89, 92
Sociocognitive theory: HBM
Perceived barriers 11/17 48, 50, 55, 58, 64, 69, 73, 80, 84, 85, 91/33, 35, 38, 42, 43, 45
Perceived adverse effects 4/5 39, 58, 60, 64/69
Perceived beneﬁts 5/11 33, 43, 45, 55, 60/42, 48, 58, 64, 69, 95
Perceived severity 3/7 42, 45, 55/39, 58, 84, 85
Perceived susceptibility 3/6 60, 69, 95/39, 45, 58
Sociocognitive theory: TPB
Perceived behavioral control 2/4 78, 82/39, 49
Intention 2/5 39, 49/33, 43, 82
Attitude 2/5 36, 82/34, 39, 78
Subjective norm 1/4 78/33, 34, 82
Self-regulation theory: SRM
Treatment beliefs†
Necessity (speciﬁc) 8/9 29, 54, 57, 63, 65, 68, 71, 79/87
Concerns (speciﬁc) 7/8 29, 54, 63, 65, 71, 79, 87/68
Harm (general) 1/3 54/63, 68
Overuse (general) 1/3 54/63, 68
Medication beliefs (not BMQ) 2/2 51, 53
Illness representations
Identity 0/6 54, 57, 61, 76, 86, 87
Consequences 1/6 76/54, 57, 61, 86, 87
Timeline 2/7 52, 54/57, 61, 76, 86, 87
Timeline (cyclical) 0/5 54, 57, 61, 76, 86
Cause 0/5 54, 57, 61, 76, 86‡
Personal control 2/6 57, 87/54, 61, 76, 86‡
Treatment control 1/3 61/54, 57
Coherence 0/3 54, 57, 61
Emotional representations 1/3 57/54, 61
HBM, health beliefs model; SRM, self-regulation model; TPB, theory of planned behavior.
* n number of studies reporting a statistically signiﬁcant (Pr 0.05) association with adherence; N number of studies that entered independent
variable into the ﬁnal regression model (results presented as counts because of heterogeneity between populations, study design, and
outcomes).
† Horne et al. [52] compared attitudinal groups, Horne et al. [59] used the Necessities-concerns differential, Gonzalez et al. [29] also measured
distrust (general).
‡ Merged medical belief/stress belief model.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 6 3 – 8 7 6 873of testing this against other theories. Applications of self-
determination theory found autonomous regulation to account
for 68% of the variance in adherence of outpatients with various
diagnoses prescribed long-term medication. Lynam et al. [32] also
found autonomous regulation to be a more robust predictor of
antiretroviral therapy adherence than locus of control; however,
again only self-efﬁcacy predicted adherence directly.
Applications of social support theory again pointed toward
the inﬂuence of more distal factors as well as self-efﬁcacy beliefs.
Simoni et al. [40] found that social support was associated with
less negative affect and greater spirituality, which, in turn, were
associated with adherence self-efﬁcacy. This model explained 8%
of the variance in adherence at 3 months and 8% of the variance
in viral load at 6 months. Halkitis and Palamar [31] found drug
use and socioeconomic status to be the signiﬁcant direct pre-
dictors of adherence, with drug use also signiﬁcantly mediating
the relationship between psychological states (level of social
support, avoidant coping, self-efﬁcacy) and adherence. Distal
personality traits were also predictors of adherence.Stilley et al. [34] found that conscientiousness and estimated
intelligence quotient accounted for 13% of the variance in
adherence, whereas Cohen et al. [37] found that activity (extra-
version dimension) and modesty (agreeableness dimension) were
signiﬁcantly associated with adherence, both accounting for 12%
of the varianceDiscussion
Overall, our comparison of the performance of models associated
with three theoretical frameworks points toward the importance
of both distal and proximal determinants, and most prominently
self-efﬁcacy or perceived control beliefs. The majority of evidence
related to the application of the health belief model, the theory of
planned behavior, and beliefs about medicines (within the self-
regulation model). Often, only single components of models
explained the variance in adherence, and the variance explained
was limited. The ﬁndings suggest that application of multiple or
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 6 3 – 8 7 6874extended models improve predictions and that consideration of
different populations within the same treatment area, or along
the illness trajectory, yield different results.
Our review has emphasized the breadth of empirical research
that has sought to predict adherence to medications using health
psychology at various stages in the adherence process. Our
results can be compared with those of a recent systematic review
of psychosocial and behavioral factors associated with initial
medication adherence [98] that identiﬁed a limited number of
studies (n ¼ 5) addressing health beliefs within which medication
beliefs, knowledge, and trust were identiﬁed as factors inﬂuenc-
ing initiation of medications. This review was, however,
restricted to medication initiation, thus focusing on only one
stage of the medication adherence process. These authors also
stressed the methodological challenges of synthesizing ﬁndings
from empirical adherence studies.
DiMatteo et al. [26] conclude that interventions should com-
prise three clinical actions: providing information and knowledge
as to how to adhere, encouraging belief in treatment and
motivation to adhere, and helping patients to overcome barriers.
O’Carroll et al. [99] also concluded that interventions to improve
adherence should target patients’ beliefs about medication.
DiMatteo et al. [26], O’Carroll et al. [99], and our review have
consistently identiﬁed the importance of self-efﬁcacy, treatment
beliefs, perceived barriers, and social support—highlighting the
need for interventions to be multifaceted.
The application of theory-driven, evidence-based models is
important in the development of effective interventions. Stavri
and Michie [8] conclude from their review that behavior, in this
case medication adherence, should be informed by an under-
standing of theoretical frameworks (e.g., sociocognitive, self-regu-
lation, and social support), and within those a range of
subordinate models (e.g., health belief model, theory of planned
behavior, and self-regulation model) and then the individual
components (e.g., perceived barriers, perceived beneﬁts, and treat-
ment beliefs). We have summarized empirical evidence for each of
these and have also identiﬁed that further credence should be
given to more distal variables, such as personality traits, more
generic beliefs, and generalized efﬁcacy beliefs, which appear also
to have a signiﬁcant role in predicting adherence to medications.
This may be achieved in practice via brief cognitive-behavioral
intervention or improved communication with health care pro-
fessionals, as evidenced in the Cochrane review of the effective-
ness of adherence-enhancing interventions. In this, modest
effects for self-efﬁcacy enhancement using individually tailored
telephone calls, information on self-management, checks on
understanding, and concerns regarding medication and empow-
erment [6] are reported, thus highlighting the potential for theory
to inform practice.
Classiﬁcation of the application of established theory may
result in a move toward the development of conceptual models
speciﬁc to adherence, rather than ad-hoc application of more
generic theories. Findings from longitudinal studies reported here
potentially add to an understanding of nonadherence and inform
the development and evaluation of interventions targeted at
different stages in the dynamic process of adherence. Turner
et al. [45], for example, demonstrate that predictors vary with
time; this principle could help explain variance in behavior across
the various stages of adherence, that is, initiation, persistence,
and discontinuation [1]. Furthermore, the consistent use of
deﬁnitions pertaining to medication adherence might improve
the power of conceptual theories to explain adherence behavior
at different stages; for example, medication beliefs may inﬂuence
initiation [e.g., 82], whereas higher self-efﬁcacy may improve
persistence [e.g., 33].
Overall, our ﬁndings support the notion that no single theory
should be used to inform the development of adherence-enhancinginterventions. Consolidation of existing models, however, could be
used as a theoretical foundation from which to lead further
empirical investigation of determinants of adherence. Identifying
signiﬁcant determinants from robust, reliable, and longitudinal
evidence establishes targets for effective adherence-enhancing
interventions with greater potential for sustainable behavior
change and improvements in health.
It should be noted, however, that the utility of these theories
can be judged only by the quality of existing empirical evidence,
which at present is limited. Further research in experimental
health psychology relating to the development of evidence-based
models of adherence to medications is encouraged, and the
potential of theories from other disciplines (e.g., behavioral
economics) should be explored. Similarly, the link between
behavior change intervention and theoretical mechanisms for
change requires a clear deﬁnition of the behavior in question
[100]. We therefore also suggest more robust adherence measure-
ment, using techniques least prone to bias, and, crucially, the use
of an agreed taxonomy of adherence to medications [1].
Key strengths of this review relate to the systematic method-
ology, the focus on studies of the highest quality,
the consideration of multiple theoretical frameworks, and the
acknowledgment that meta-analysis was inappropriate for the
sample of studies included in our review. Most of the studies
identiﬁed, however, were cross-sectional, which cannot accom-
modate dynamic theoretical propositions, capture the entire
process of adherence, or make inferences concerning causality
of effect. It is also recognized that studies investigating patients
who are willing to participate in research may miss people who
do not seek or have dropped out of health care, which may
introduce sampling bias and limit generalizability to the least
adherent patients. Our review also excluded studies with partic-
ipants not responsible for the taking of their own medicines.
The review was limited by the degree to which the factors
studied, and the theories/models on which they were based,
compared with one another. The assignment of the independent
variables to the theoretical constructs had to be assumed in some
cases in which published articles lacked speciﬁcity. Only 5 of the
67 studies distinctly tested multiple models; all these studies
were associated with sociocognitive theory. Heterogeneity among
studies, originating from multiple sources, precluded any quan-
titative synthesis of the results although our narrative approach
captured the key elements of the ﬁndings. The systematic
approach to reviewing the studies ensured a rigorous assessment
of quality and the combinability of studies in which to consider
(and reject) the appropriateness of pooling the data [97].Conclusions
The ﬁndings of this systematic review suggest that health
psychology theories are useful at predicting adherence to med-
ications; however, in all cases, the determinants and variation in
their measurement were sufﬁciently complicated that no indi-
vidual theory or model ever explained more than a limited
amount of the variability in adherence behavior. Nonetheless,
our ﬁndings have relevance for theory building and intervention
development, and potentially for clinical practice. Consolidation
of behavioral models and their components may provide a
strengthened theoretical basis for the development and assess-
ment of effective adherence-enhancing interventions.Acknowledgments
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